ପ୍ରୋଷ୍ଟେଟ୍ କ୍ୟାନ୍ସର
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
କେଉଁଠିକୁ ଯିବେ
ଏହି trial ପାଇଁ ଭାରତର 8ଟି hospital ପିଲାମାନଙ୍କୁ ନେଉଛି।
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that keeps progressing even when the amount of male sex hormones like testosterone (also called androgens) is reduced to very low levels. To reduce androgen levels in prostate cancer patients, androgen deprivation therapy (ADT) is often used. As androgens stimulate the growth of prostate cancer cells, low levels are needed to reduce or slow the growth of these tumors. In men …
ସ୍ପୋନ୍ସର: ବାୟର
ClinicalTrials.gov ରେ NCT05348876
ରେଜିଷ୍ଟ୍ରିରେ ଶେଷ ଅପଡେଟ୍ 6 ଜୁଲାଇ 2026 · ଆମ ଦ୍ୱାରା ପଢ଼ାଯାଇଛି 20 ଅକ୍ଟୋବର 2026